Phase IIb Multi-Center Randomised Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus (B-Clear)

Brief description of study

GSK3228836 (the study drug) is an experimental new drug for treating chronic hepatitis B (CHB) and is not approved by the United States Food and Drug Administration (FDA) for use in people living with CHB. CHB is caused by the hepatitis B virus, which infects the liver and can cause damage. Most people who become infected as an adult with the virus get rid of it without any problems. People who become infected as a child may be more likely to develop chronic infection. In some people, the immune system (which helps your body protect you from getting sick) is unable to get rid of the hepatitis B virus and this results in lifelong infection that can cause serious liver disease.


Clinical Study Identifier: s20-00722
ClinicalTrials.gov Identifier: NCT04449029
Principal Investigator: James S Park.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.